Skip to main content
ELI LILLY & Co logo

ELI LILLY & Co — Investor Relations & Filings

Ticker · LLY ISIN · US5324571083 LEI · FRDRIPF3EKNDJ2CQJL29 US Manufacturing
Open in API
Filings indexed 3,870 across all filing types
Latest filing 2019-02-08 M&A Activity
Country US United States of America
Listing US LLY

About ELI LILLY & Co

https://www.lilly.com/

Eli Lilly and Company is a global, research-based medicine company that discovers, develops, manufactures, and sells pharmaceutical products. The company focuses on creating treatments in key therapeutic areas, including diabetes, obesity, immunology, oncology, and neuroscience. Leveraging biotechnology and chemistry, it develops medicines for some of the world's most significant health challenges. Historically known for the commercialization of insulin, the company continues to be a major provider of therapies for chronic diseases. Its stated purpose is to unite caring with discovery to create medicines that make life better for people around the world.

Recent filings

Filing Released Lang Actions
425 Filing
M&A Activity Classification · 95% confidence The document is filed by Eli Lilly and Company pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with a merger or acquisition transaction. The text describes an exchange offer by Eli Lilly to exchange shares of Elanco Animal Health for shares of Lilly common stock. It includes detailed terms of the exchange offer, indicative exchange ratios, and references to a Prospectus and other related documents. The presence of Rule 425 filing and the detailed description of the exchange offer indicate this is related to merger and acquisition activity. The document is not a full annual or quarterly report, nor is it a proxy or voting result announcement. It is a communication related to a takeover bid or merger transaction. Therefore, the appropriate classification is M&A Activity (Code: TAR). The document length and content support a high confidence in this classification.
2019-02-08 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with business combinations or exchange offers. The text discusses an exchange offer by Eli Lilly and Company to exchange shares of Elanco Animal Health Incorporated for Lilly common stock. It provides information about the exchange offer, including instructions for employee plan participants, disclaimers about voluntary participation, and references to the prospectus and other SEC filings (Form S-4 and Schedule TO). There is no financial data or detailed financial analysis present; rather, it is a communication providing information about the exchange offer terms and where to find further documents. This type of document is a merger-related communication under Rule 425, which is typically classified under Merger & Acquisition (MA) filings. The document is not an announcement of a report, nor is it a full report itself, but a communication related to a merger/acquisition transaction.
2019-02-08 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is a communication toolkit related to the divestiture of Lilly's remaining ownership in Elanco through an exchange offer. It references the filing of an S-4 registration statement with the SEC, which is a merger and acquisition related filing. The text explains the process, regulatory constraints, and provides Q&A about the divestiture and exchange offer. It does not contain financial statements or detailed financial data itself but rather serves as an announcement and informational guide about the divestiture process and upcoming filings. The presence of the S-4 registration statement and the nature of the content focusing on the divestiture and exchange offer clearly indicate this is related to merger and acquisition activity. Therefore, the appropriate classification is Merger & Acquisition (MA).
2019-02-08 English
425 Filing
Merger & Acquisition Classification · 95% confidence The document is filed pursuant to Rule 425 under the Securities Act of 1933, which relates to communications in connection with business combinations or exchange offers. The text is a divestiture video script discussing Eli Lilly's intention to divest its remaining ownership in Elanco through an exchange offer. It includes forward-looking statements and references to forthcoming SEC filings such as a registration statement and Schedule TO, which are typical for merger or acquisition-related communications. The document is not a full report but a communication related to a transaction. Therefore, it fits best under the category for merger and acquisition communications under Rule 425 filings, which corresponds to the 'Merger & Acquisition' (MA) category.
2019-02-08 English
Eli Lilly and Company: Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
Earnings Release Classification · 95% confidence The document is a detailed press release from Eli Lilly and Company reporting strong fourth-quarter and full-year 2018 financial results, including revenue, net income, earnings per share, and guidance for 2019. It contains comprehensive financial data, including GAAP and non-GAAP measures, detailed discussion of revenue drivers, expenses, tax impacts, and business developments such as acquisitions and regulatory approvals. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content aligns with an Earnings Release (ER) as it provides initial quarterly and annual financial results with key highlights and management commentary. It is not a full Annual Report (10-K) or Interim Report (IR) because it is a press release focused on earnings results and guidance rather than a comprehensive report with full financial statements and notes. Therefore, the appropriate classification is Earnings Release (ER). FY 2018
2019-02-07 French
FORM 4
Director's Dealing
2019-02-07 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.